Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the most promising penny stocks under $5. On July 24, Rocket Pharmaceuticals announced a strategic corporate reorganization and pipeline prioritization to focus its resources on its adeno-associated virus/AAV cardiovascular platform and the regulatory submission for KRESLADI (formerly RP-L201) for severe leukocyte adhesion deficiency-I/LAD-I.

The company is implementing a workforce reduction of ~30%. This, along with other cost-saving measures, is expected to decrease Rocket’s 12-month operating expenses by ~25%. As a result, the company anticipates that its current cash resources will fund operations into Q2 2027.

This estimate does not account for any potential proceeds from a Priority Review Voucher, which may be granted upon the FDA approval of KRESLADI. As part of this realignment, the company anticipates delays in the Fanconi Anemia (FA; RP-L102) and Pyruvate Kinase Deficiency (PKD; RP-L301) programs, with FDA approval for RP-L102 no longer expected in 2026.

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the US.

While we acknowledge the potential of RCKT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.